Media coverage about Akari Therapeutics PLC (NASDAQ:AKTX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akari Therapeutics PLC earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.1915182514458 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Akari Therapeutics PLC (NASDAQ AKTX) opened at 4.25 on Thursday. The company has a 50-day moving average price of $5.80 and a 200-day moving average price of $6.85. Akari Therapeutics PLC has a 12-month low of $3.18 and a 12-month high of $22.20. The stock’s market capitalization is $50.05 million.

A number of research analysts recently issued reports on AKTX shares. William Blair reiterated an “outperform” rating on shares of Akari Therapeutics PLC in a report on Tuesday, July 4th. Chardan Capital reiterated a “neutral” rating and issued a $2.50 target price (down from $6.00) on shares of Akari Therapeutics PLC in a report on Friday, August 11th. Zacks Investment Research upgraded Akari Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. ValuEngine upgraded Akari Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Monday, September 11th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $15.00 target price on shares of Akari Therapeutics PLC in a report on Friday, September 22nd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. Akari Therapeutics PLC currently has an average rating of “Hold” and an average price target of $8.00.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-akari-therapeutics-plc-aktx-share-price/1654977.html.

Akari Therapeutics PLC Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Insider Buying and Selling by Quarter for Akari Therapeutics PLC (NASDAQ:AKTX)

Receive News & Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.